Financial reports
10-Q
2024 Q2
Quarterly report
12 Aug 24
10-Q
2024 Q1
Quarterly report
14 May 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
10-Q
2023 Q1
Quarterly report
5 May 23
ARS
2022 FY
Annual report to shareholders
20 Apr 23
10-K
2022 FY
Annual report
16 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
Current reports
8-K
Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update
12 Aug 24
8-K
Submission of Matters to a Vote of Security Holders
13 Jun 24
8-K
Immunome Reports First Quarter 2024 Financial Results and Provides Business Update
14 May 24
8-K
Departure of Directors or Certain Officers
30 Apr 24
8-K
Departure of Directors or Certain Officers
25 Apr 24
8-K
Immunome Reports Full-Year 2023 Financial Results and Provides Update on Recently Acquired Assets
28 Mar 24
8-K
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
26 Mar 24
8-K
Other Events
14 Feb 24
8-K
Results of Operations and Financial Condition
13 Feb 24
8-K
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
6 Feb 24
Registration and prospectus
424B5
Prospectus supplement for primary offering
14 May 24
S-3ASR
Automatic shelf registration
3 Apr 24
S-3ASR
Automatic shelf registration
3 Apr 24
424B5
Prospectus supplement for primary offering
14 Feb 24
424B5
Prospectus supplement for primary offering
13 Feb 24
S-3ASR
Automatic shelf registration
13 Feb 24
S-8
Registration of securities for employees
2 Feb 24
S-3
Shelf registration
16 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Nov 23
425
Business combination disclosure
21 Sep 23
Proxies
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
DEFA14A
Additional proxy soliciting materials
20 Apr 23
DEF 14A
Definitive proxy
20 Apr 23
PRE 14A
Preliminary proxy
7 Apr 23
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEF 14A
Definitive proxy
29 Apr 22
DEFA14A
Additional proxy soliciting materials
16 Apr 21
DEF 14A
Definitive proxy
16 Apr 21
Other
EFFECT
Notice of effectiveness
28 Nov 23
CORRESP
Correspondence with SEC
22 Nov 23
UPLOAD
Letter from SEC
20 Nov 23
EFFECT
Notice of effectiveness
29 Aug 23
CORRESP
Correspondence with SEC
25 Aug 23
UPLOAD
Letter from SEC
11 Aug 23
EFFECT
Notice of effectiveness
15 Oct 21
CORRESP
Correspondence with SEC
12 Oct 21
UPLOAD
Letter from SEC
8 Oct 21
EFFECT
Notice of effectiveness
2 Jun 21
Ownership
4
Max Rosett
20 Sep 24
144
Notice of proposed sale of securities
19 Sep 24
SC 13D/A
Barchas Isaac
21 Aug 24
4
JEAN JACQUES BIENAIME
19 Aug 24
4
Jack Higgins
19 Aug 24
144
Notice of proposed sale of securities
15 Aug 24
4
CLAY B SIEGALL
13 Aug 24
4
Sandra G. Stoneman
13 Aug 24
4
Kinney Horn
13 Aug 24
4
Bruce Turner
13 Aug 24